OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab (STAR)
Recruitment status was: Recruiting
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
|Official Title:||OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab|
- Gains in visual acuity [ Time Frame: Baseline and months 1, 2, 3, 4, 5, and 6 ]Gains in visual acuity will be assessed by comparing best corrected visual acuity at each follow up appointment by the standardized vision testing, early treatment diabetic retinopathy study (ETDRS) visual acuity test. The ETDRS visual acuity test was first developed to effectively evaluate visual changes following panretinal photocoagulation in patients with diabetic retinopathy. This method of measuring visual acuity was more accurate than previous methods, and thus has become the global standard, especially for clinical trials where it is essential to have utmost accuracy.
- Changes in intraocular pressure [ Time Frame: Baseline and months 1, 2, 3, 4, 5 and 6 ]To be measured by tonometry
- Rates of re-treatment [ Time Frame: Months 1, 2, 3, 4, 5 and 6 ]To be measured by recording each drug administration date
- Rate of vision loss [ Time Frame: Baseline and months 1, 2, 3, 4, 5 and 6 ]To be measured by ETDRS visual acuity testing and compared over the course of the study
- Rate of cataract progression [ Time Frame: Baseline and months 1, 2, 3, 4, 5, and 6 ]Measured at each appointment with a slit lamp examination
- Changes in choroid vessel activity in lesion growth and activity at choroid [ Time Frame: Baseline and months 1, 2, 3, 4, 5 and 6 ]The changes in blood vessel lesion growth and activity will be measured by OCT (Ocular Coherence Tomography) and fundus fluorescein angiography to assess choroidal neovascular leakage
|Study Start Date:||March 2011|
|Estimated Study Completion Date:||March 2016|
|Estimated Primary Completion Date:||February 2016 (Final data collection date for primary outcome measure)|
Placebo Comparator: Ranibizumab
Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
Other Name: Lucentis
Active Comparator: Ranibizumab and OZURDEX
Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections. Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and OZURDEX will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration.
OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
Other Name: Dexamethasone
Age Related Macular Degeneration (ARMD or AMD) is the leading cause of blindness in North America. There are two types of ARMD: dry and wet. Both forms of ARMD cause a progressive loss of central vision, the part of your vision that allows you to read, drive and see images in sharp detail directly in front of you. The wet form is typically more severe and is characterized by the growth and leakage of small blood vessels into the choroid layer of the eye, or the back of the eye. These leaking blood vessels disrupt the structure and function of the eye, causing loss of vision, particularly the sharp vision created by the macula area of the eye.
Upon being accepted to the study, participants will be randomly divided into two groups. One group will receive both ranibizumab and OZURDEX injections and the other group will receive ranibizumab injections and a placebo treatment. To participants in this group, there will be the appearance of a second injection but no actual injection will take place. An individual not connected to the study will assign participants to a group based on a computer-generated system, giving participants at 50% chance of being placed in either group. During the study, participants will not know which group they are in, but will be able to know once the study is finished.
Participants will be asked to come in for an initial assessment to determine their starting visual abilities and medical history. On the next appointment, participants will receive the first treatment injections. They will be asked to come into the clinic every month for six (6) months total for treatment injections and testing. At each appointment, study investigators will take 3-D images of the retina (the back of the eye) using an Optical Coherence Tomography (OCT) imaging device, test eye pressure and determine if there are any signs of infection or inflammation from the injections. On months 1, 3 and 6 investigators will also test vision using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts, contrast sensitivity using a standard contrast sensitivity chart (The Pelli-Robson chart) and take images of the blood vessel growth using a coloured dye (fluorescein) to help see blood vessels. Before every treatment, anesthetic eye drops (proparacaine) will be applied to the eye so participants will not feel the injections. Participants will be given antibiotic eye drops (Zymar®) and will be asked to apply the drops 4 times a day for a few days after the injection to prevent infection.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01243086
|Contact: Varun Chaudhary, M.D., FRCSC||905-573-7777 ext email@example.com|
|Contact: Joshua Barbosa||905-573-7777 ext firstname.lastname@example.org|
|St. Joseph's Healthcare Hamilton Regional Eye Centre||Recruiting|
|Hamilton, Ontario, Canada, L8G 5E4|
|Contact: Varun Chaudhary, MD, FRCSC 905-573-7777 ext 38058 email@example.com|
|Contact: Joshua Barbosa 905-573-7777 ext 38070 firstname.lastname@example.org|
|Principal Investigator: Varun Chaudhary, MD, FRCSC|
|Sub-Investigator: Emmanuel Mavrikakis, MD, PhD|
|Sub-Investigator: Forough Farrokhyar, PhD|
|Sub-Investigator: Joshua Barbosa|
|Principal Investigator:||Varun Chaudhary, M.D., FRCSC||McMaster University|